HKSE · 0575.HK
Regent Pacific Group Limited
HK$0.87+HK$0.02 (+2.35%)
Regent Pacific Group Limited’s quoted price sits in the lower half of its reported 52-week range, 28.69% below the high.
Loading market information…
HKSE · 1498.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:38 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
PuraPharm Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 47.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
PuraPharm Corporation Limited’s forward annual dividend is HK$0.02 per share, paid annual. The forward yield is 8.29% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
PuraPharm Corporation Limited’s next earnings report is currently expected on Mar 31, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PuraPharm Corporation Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hong Kong, Mainland China, and international markets. Its operations are structured into five key divisions: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers a range of over-the-counter health solutions under brand names such as PuraGold, Haveron, Oncozac, and Immuzac. Beyond product sales, PuraPharm provides a clinic management system for general Chinese medical practices and operates its own chain of Nong's Chinese medicine clinics, which deliver both traditional medical services and CCMG products. The company also oversees the cultivation and trade of raw Chinese herbs, in addition to manufacturing and selling traditional Chinese medicine decoction pieces. Complementing its product offerings, it delivers modernized Chinese medicine services and diagnostic consultations. PuraPharm distributes its goods to hospitals, healthcare institutions, medical professionals, and directly to consumers via an online store. The company currently manages 43 Nong's clinics in Hong Kong and one in Guangxi, China. Founded in 1998, its headquarters are located in Tai Po, Hong Kong.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:02 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 21, 2023 |
| -HK$0.20-281.82% vs estimate |
| HK$217.31M-68.07% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$0.87+HK$0.02 (+2.35%)
Regent Pacific Group Limited’s quoted price sits in the lower half of its reported 52-week range, 28.69% below the high.
HK$0.09HK$0.00 (0.0%)
Tianda Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 35.97% below the high.
HK$0.05HK$0.00 (0.0%)
Extrawell Pharmaceutical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 55.65% below the high.
HK$0.65-HK$0.08 (-10.96%)
King International Investment Limited’s quoted price sits in the lower half of its reported 52-week range, 59.12% below the high.
HK$0.19-HK$0.02 (-10.38%)
Kelfred Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 65.45% below the high.
HK$0.25-HK$0.00 (-0.41%)
China Regenerative Medicine International Limited’s quoted price sits in the lower half of its reported 52-week range, 62.88% below the high.
HK$0.07+HK$0.00 (+4.76%)
China Health Group Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.76% below the high.
HK$0.07-HK$0.00 (-1.35%)
China Healthwise Holdings Ltd.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
